Page last updated: 2024-10-15

8-azaxanthine

Description

methanochondroitin: a heteropolysaccharide from cell wall which resembles the eukaryotic chondroitin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135400688
CHEMBL ID219341
CHEBI ID40850
SCHEMBL ID308420
SCHEMBL ID16334985
SCHEMBL ID8177726
MeSH IDM0069529

Synonyms (51)

Synonym
v-triazolo[4,7-diol
usaf cb-26
1h-v-triazolo[4,7(4h,6h)-dione
nsc 756
wln: t56 bmnn fmvmvj
xanthazol
nsc756
2,6-dioxy-8-azapurine
1h-1,3-triazolo[4,5-d]pyrimidine-5,7(4h,6h)-dione
nsc-756
3,4-dihydrotriazolo[4,5-d]pyrimidine-5,7-dione
8-azaxanthine
1468-26-4
photocarcinorin
DB01875
8-azaxanthin
einecs 215-992-2
v-triazolo(4,5-d)pyrimidine-5,7-diol (van)
1h-v-triazolo(4,5-d)pyrimidine-5,7(4h,6h)-dione
1h-1,2,3-triazolo(4,5-d)pyrimidine-5,7(4h,6h)-dione
v-triazolo(4,5-d)pyrimidine-5,7-diol
ai3-25011
CHEBI:40850 ,
2,3-dihydrotriazolo[4,5-e]pyrimidine-5,7-dione
azaxanthine
3h-[1,2,3]triazolo[4,5-d]pyrimidine-5,7(4h,6h)-dione
CHEMBL219341
2,3-dihydrotriazolo[4,5-d]pyrimidine-5,7-dione
AKOS003595889
unii-97mrz3zy2u
97mrz3zy2u ,
1,4-dihydrotriazolo[5,4-e]pyrimidine-5,7-dione
103939-18-0
FT-0621503
103939-01-1
methanochondroitin
SCHEMBL308420
SCHEMBL16334985
SCHEMBL8177726
1h-[1,2,3]triazolo[4,5-d]pyrimidine-5,7(4h,6h)-dione
1h-1,2,3-triazolo[4,5-d]pyrimidine-5,7(4h,6h)-dione
KVGVQTOQSNJTJI-UHFFFAOYSA-N
v-triazolo[4,5-d]pyrimidine-5,7(4h,6h)-dione
3h-[1,2,3]triazolo[4,5-d]pyrimidine-5,7(4h,6h)-dione #
[1,2,3]triazolo[4,5-d]pyrimidine-5,7-diol
1h-v-triazolo[4,5-d]pyrimidine-5,7(4h,6h)-dione (8ci)
2,4-dihydrotriazolo[4,5-d]pyrimidine-5,7-dione
DTXSID30862673
Q27120407
PD060231
3h,4h,5h,6h,7h-[1,2,3]triazolo[4,5-d]pyrimidine-5,7-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triazolopyrimidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID252792Insulin release in rat pancreatic beta-cells after 15 minutes of administration at 1 mM was measured2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
AID274547Inhibition of [3H]hypoxanthine uptake in Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID545994Inhibition of Trypanosoma cruzi dihydroorotate dehydrogenase by isothermal titration calorimetry2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
AID274548Antiplasmodial activity against Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID274550Inhibition of Plasmodium falciparum HGXPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (25.58)18.7374
1990's10 (23.26)18.2507
2000's11 (25.58)29.6817
2010's9 (20.93)24.3611
2020's2 (4.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (4.44%)4.05%
Observational0 (0.00%)0.25%
Other43 (95.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]